Related Experiment Video
Updated: Aug 14, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Effect of Vinorelbine on cell growth and apoptosis induction in human osteosarcoma in vitro
Laura Roncuzzi1, Gianpiero Marti, Daniela Baiocchi
1Department of Experimental Pathology, University of Bologna, Italy.
Abstract:
Vinorelbine (VNR) is a semi-synthetic vinca alkaloid known to exert its antitumour activity by interfering with the polymerisation of tubulin. It has shown a broad spectrum of activity in some advanced carcinomas of lung, breast and ovary. This report demonstrates for the first time the antiproliferative effect of VNR and its molecular mechanism in human osteosarcoma in vitro. TP53 wild-type HOS cells and TP53 mutated MG-63 cells were chosen for this study. In each cell line, VNR caused a significant dose- and time-dependent growth inhibition and induced apoptotic death independent of TP53 status. Phosphorylation and/or alteration of Bcl-2 were not induced by VNR, thereby indicating a new pathway utilised by the drug to induce apoptosis in this tumour in vitro. VNR produced a down-regulation of cyclin D1 and an up-regulation of p53 expression in TP53 wild-type HOS cells, whereas no alteration in cyclin D1 expression was evident in the TP53 negative MG-63 cells. These data suggest a new potential use for Vinorelbine as a therapeutic agent against human osteosarcoma.
Insights
Vinorelbine (VNR) effectively inhibits human osteosarcoma cell growth and induces apoptosis, independent of TP53 status. This study reveals VNR
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Vinorelbine (VNR) is a semi-synthetic vinca alkaloid with demonstrated antitumour activity in various advanced carcinomas.
- Its mechanism involves interference with tubulin polymerization, a key process in cell division.
Purpose of the Study:
- To investigate the antiproliferative effects of Vinorelbine (VNR) on human osteosarcoma cells in vitro.
- To elucidate the molecular mechanisms underlying VNR's action in osteosarcoma, including its impact on cell death pathways and specific protein expressions.
Main Methods:
- Utilized TP53 wild-type HOS and TP53 mutated MG-63 human osteosarcoma cell lines.
- Assessed VNR's impact on cell growth inhibition and apoptosis induction in a dose- and time-dependent manner.
- Analyzed changes in Bcl-2, cyclin D1, and p53 expression levels following VNR treatment.
Main Results:
- VNR demonstrated significant dose- and time-dependent growth inhibition and induced apoptosis in both cell lines, irrespective of TP53 mutation status.
- VNR did not induce phosphorylation or alteration of Bcl-2, suggesting a novel apoptotic pathway.
- VNR downregulated cyclin D1 and upregulated p53 in TP53 wild-type HOS cells, while cyclin D1 expression remained unchanged in TP53-negative MG-63 cells.
Conclusions:
- Vinorelbine exhibits potent antiproliferative and pro-apoptotic effects on human osteosarcoma cells in vitro.
- The drug appears to induce apoptosis through a TP53-independent pathway, distinct from Bcl-2 modulation.
- These findings suggest Vinorelbine as a potential therapeutic agent for human osteosarcoma.
More Related Videos
06:13Colony Formation Assay Detecting the Proliferative Capacity of LncRNA-knockdown Osteosarcoma Cells
Published on: January 16, 2026
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018